



Ludvig Sjöberg as new CEO of Moroxite T

The Board of Directors of Moroxite T AB has appointed Ludvig Sjöberg as the new CEO. Ludvig will take over as CEO of Moroxite T on May 1, 2024.

Ludvig has extensive experience in life science and medical technology. He comes most recently from the position as CEO of the kidney transplant company UGLK Science AB, and has previously worked with business and technology development at Igelösa Life Science AB and with the production of CE-marked lung transplant equipment at Vivoline Medical AB.

"It will be extremely exciting to continue to build and develop Moroxite T for the treatment of bone cancer. I look forward with great confidence to Ludvig Sjöberg, together with employees and partners, taking the company's unique ceramic carrier platform to regulatory approval and market introduction."

Lars Lidgren

Chairman of the Board

Moroxite T AB

Moroxite T is a lifescience company with focus on hindering tumor progression and impeding metastasis. Our novelty lies in a protected carrier platform for cancer therapy using hydroxyapatite for local drug delivery. In Moroxite T, we are committed to developing innovative targeted oncological treatment.

Moroxite T's proprietary technology platform is well-protected by patent and pending patent applications.

Read more on www.moroxitet.com.

Moroxite T AB

Kung Oskars väg 11C, 222 35, Lund, Sweden
Wu.Moroxidet.com